Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.

Autor:	Lubitz CC; Department of Surgery; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital Institute for Technology Assessment, Boston, Massachusetts, USA., Sadow PM; Department of Pathology; Harvard Medical School, Boston, Massachusetts, USA., Daniels GH; Department of Medicine; Harvard Medical School, Boston, Massachusetts, USA.; Department of Thyroid Unit; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Wirth LJ; Department of Medicine; Harvard Medical School, Boston, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	Thyroid : official journal of the American Thyroid Association [Thyroid] 2021 Oct; Vol. 31 (10), pp. 1451-1462. Date of Electronic Publication: 2021 Jun 22.
DOI:	10.1089/thy.2020.0962
Abstrakt:	Background: Thyroid cancer is a common malignancy whose detection has increased significantly in past decades. Most of the increased incidence is due to detection of early well-differentiated thyroid cancer, but the incidence of more advanced thyroid cancers has increased as well. Recent methodological advancements have allowed for a deep understanding of the molecular underpinnings of the various types of thyroid cancer. Summary: Thyroid cancers harbor a high frequency of potential druggable molecular alterations, including the highest frequency of oncogenic driver kinase fusions seen across all solid tumors. Analyses of poorly differentiated and anaplastic thyroid carcinoma confirmed that these tumors develop from more well-differentiated follicular-derived thyroid cancers through acquired additional mutations. The recognition of driver genomic alterations in thyroid cancers not only predicts tumor phenotype but also now can inform treatment approaches. Conclusions: Major progress in understanding the oncogenic molecular underpinnings across the array of thyroid cancers has led to considerable gains in gene-specific systemic therapies for many cancers. This article focuses on the molecular characteristics of aggressive follicular-derived thyroid cancers and medullary thyroid cancer and highlights advancements in treating thyroid cancer in the era of targeted therapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu